Free tool
FAERS Monitor: Astagraf Xl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204096 or its brand name (Astagraf Xl, Tacrolimus). Reports on generic versions are filed under their own applications.
Reports
353
Serious
192
54% of reports
Hospitalization
99
Death reported
40
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death27
- inappropriate schedule of drug administration20
- diarrhoea15
- hospitalisation15
- off label use14
- malaise13
- pneumonia13
- nausea11
- treatment noncompliance11
- kidney transplant rejection10
- pyrexia10
- vomiting10
- immunosuppressant drug level decreased9
- tremor9
- asthenia7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 46 |
| 2015 | 57 |
| 2016 | 59 |
| 2017 | 57 |
| 2018 | 45 |
| 2019 | 10 |
| 2020 | 13 |
| 2021 | 6 |
| 2022 | 11 |
| 2023 | 12 |
| 2024 | 21 |
| 2025 | 6 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,806 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| immunosuppressant drug level decreasedSignal | 9 | 450.7 | 235.9 | 3,574 |
| kidney transplant rejectionSignal | 10 | 124.4 | 67.5 | 1,102 |
| inappropriate schedule of drug administrationSignal | 20 | 16.8 | 10.9 | 282 |
| treatment noncomplianceSignal | 11 | 12.0 | 6.7 | 100 |
| hospitalisationSignal | 15 | 5.8 | 3.5 | 56 |
| tremorSignal | 9 | 3.2 | 1.7 | 12 |
| pneumoniaSignal | 13 | 2.4 | 1.4 | 9 |
| death | 27 | 1.9 | 1.3 | 10 |
| malaise | 13 | 1.8 | 1.0 | 4 |
| pyrexia | 10 | 1.7 | 0.9 | 2 |
| diarrhoea | 15 | 1.4 | 0.8 | 1 |
| vomiting | 10 | 1.3 | 0.7 | 0 |
| asthenia | 7 | 1.1 | 0.5 | 0 |
| off label use | 14 | 1.0 | 0.6 | 0 |
| nausea | 11 | 0.8 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.